Automate Your Wheel Strategy on VTRS
With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTRS
- Rev/Share 12.0226
- Book/Share 13.2741
- PB 0.8008
- Debt/Equity 0.9295
- CurrentRatio 5.8158
- ROIC -0.0632
- MktCap 12393198100.0
- FreeCF/Share 1.585
- PFCF 6.6659
- PE -3.5951
- Debt/Assets 0.3768
- DivYield 0.0452
- ROE -0.1992
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VTRS | Goldman | -- | Neutral | -- | $10 | June 6, 2025 |
News
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Published: August 19, 2025 by: PRNewsWire
Sentiment: Neutral
PITTSBURGH , Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions.
Read More
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH , Aug. 11, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease (CKD). IDA is a common complication of CKD and is associated …
Read More
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Read More
Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Theodora Mistras - Chief Financial Officer William Szablewski - Former Head of Capital Markets Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Bhavin Patel - Bank of America, Research Division David A.
Read More
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Negative
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Read More
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Published: August 01, 2025 by: PRNewsWire
Sentiment: Neutral
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025. The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models.
Read More
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Read More
Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. (NASDAQ: VTRS) breached their fiduciary duties to shareholders.
Read More
Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Conference Call Participants Unidentified Analyst Great.
Read More
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Read More
Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Yuchen Ding Good morning, and welcome to the day 2 of the Jefferies Healthcare Conference.
Read More
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Class Action Filed Against Viatris Inc. (VTRS) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151471&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
VTRS DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / WHY: New York, N.Y., June 3, 2025.
Read More
Class Action Lawsuit Filed: Viatris Inc. (VTRS) - Join by June 3, 2025 - Contact Levi & Korsinsky
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151460&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Viatris Inc. (VTRS)
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151437&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq.
Read More
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Viatris Inc. (VTRS) Investors of June 3, 2025 Deadline
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151411&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Urges Viatris (VTRS) Shareholders to Act Before Lead Plaintiff Deadline June 3, 2025
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151395&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.
Read More
FINAL REMINDER VTRS DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Viatris Inc. Investors to Participate in the Class Action Lawsuit
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period").
Read More
June 3, 2025 Deadline Approaching: Join Class Action Against Viatris Inc. (VTRS) - Contact Levi & Korsinsky
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151348&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
Read More
VIATRIS 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / June 2, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NasdaqGS:VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period").
Read More
VTRS STOCK ALERT: Viatris Inc. Shareholders With Losses May Have Been Affected by Fraud - Contact BFA Law by Tomorrow's June 3 Deadline
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.
Read More
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151309&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options
Read More
Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). IF YOU SUFFERED A LOSS ON YOUR VIATRIS INVESTMENTS, CLICK HERE BEFORE JUNE 3, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Reminds Investors of June 3, 2025
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151278&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky Before June 3, 2025 to Join Class Action
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151253&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
About Viatris Inc. (VTRS)
- IPO Date 1980-03-17
- Website https://www.viatris.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Scott Andrew Smith
- Employees 32000